Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 64
Filter
Add more filters










Publication year range
1.
Ann Rheum Dis ; 76(1): 17-28, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27697765

ABSTRACT

Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines. The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined. First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Second, the rheumatologist is responsible for CVD risk management in patients with IJD. Third, the use of non-steroidal anti-inflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society. Ten recommendations were defined, of which one is new and six were changed compared with the 2009 recommendations. Each designated an appropriate evidence support level. The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased. This underscores the need for CVD risk management in these patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.


Subject(s)
Cardiovascular Diseases/prevention & control , Physician's Role , Rheumatology , Risk Management , Adrenal Cortex Hormones/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Psoriatic/complications , Arthritis, Psoriatic/drug therapy , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/drug therapy , Cardiovascular Diseases/etiology , Directive Counseling , Humans , Life Style , Risk Assessment , Risk Factors , Risk Management/methods , Spondylitis, Ankylosing/complications , Spondylitis, Ankylosing/drug therapy
2.
RMD Open ; 2(1): e000241, 2016.
Article in English | MEDLINE | ID: mdl-27110386

ABSTRACT

OBJECTIVES: Clinical joint activity is a strong predictor of joint damage in rheumatoid arthritis (RA), but progression of damage might increase despite clinical inactivity of the respective joint (silent progression). The aim of this study was to evaluate the prevalence of silent joint progression, but particularly on the patient level and to investigate the duration of clinical inactivity as a marker for non-progression on the joint level. METHODS: 279 patients with RA with any radiographic progression over an observational period of 3-5 years were included. We obtained radiographic and clinical data of 22 hand/finger joints over a period of at least 3 years. Prevalence of silent progression and associations of clinical joint activity and radiographic progression were evaluated. RESULTS: 120 (43.0%) of the patients showed radiographic progression in at least one of their joints without any signs of clinical activity in that respective joint. In only 7 (5.8%) patients, such silent joint progression would go undetected, as the remainder had other joints with clinical activity, either with (n=84; 70.0%) or without (n=29; 24.2%) accompanying radiographic progression. Also, the risk of silent progression decreases with duration of clinical activity. CONCLUSIONS: Silent progression of a joint without accompanying apparent clinical activity in any other joint of a patient was very rare, and would therefore be most likely detected by the assessment of the patient. Thus, full clinical remission is an excellent marker of structural stability in patients with RA, and the maintenance of this state reduces the risk of progression even further.

3.
Ann Rheum Dis ; 74(11): 2022-7, 2015 Nov.
Article in English | MEDLINE | ID: mdl-24962872

ABSTRACT

OBJECTIVE: To validate ultrasound (US) for measuring metacarpal cartilage thickness (MCT), by comparing it with anatomical measurement using cadaver specimens. To correlate US MCT with radiographic joint space narrowing (JSN) or width (JSW) in patients with rheumatoid arthritis (RA). METHODS: Bilateral metacarpophalangeal (MCP) joints of 35 consecutive outpatients, with recent hand X-rays, were included in the analysis. Metacarpal and phalangeal cartilage of MCP 2-5 was assessed bilaterally by US. JSW and JSN were evaluated on X-rays by the van der Heijde modified Sharp method (vdHS). In addition, cadaver specimens of MCP 2-5 joints (n=19) were evaluated by anatomical measurement and US. RESULTS: The agreement (intraclass correlation coefficient) between sonographic and anatomical MCT on cadaver specimens of MCP joints was 0.61. MCT of individual MCP joints correlated with individual MCP JSN (r=-0.32, p<0.001) and individual MCP JSW (r=0.72, p<0.001). No correlation was found between phalangeal cartilage thickness and JSN in individual MCP joints. The US MCT summary score for MCP joints 2-5 correlated with summary scores for JSW (r=0.78, p<0.001), JSN (r=-0.5, p<0.001), erosion score of the vdHS (r=-0.39, p<0.001) and total vdHS (r=-0.47, p<0.001). CONCLUSIONS: Sonographic cartilage assessment in MCPs is closely related to anatomical cartilage thickness. Both JSW and JSN by radiography represent cartilage thickness in the MCP joints of patients with RA quite well. Thus, US is a valid tool for measuring MCT if radiographs are not available or in case of joint malalignment.


Subject(s)
Arthritis, Rheumatoid/diagnostic imaging , Cartilage, Articular/diagnostic imaging , Metacarpophalangeal Joint/diagnostic imaging , Aged , Aged, 80 and over , Arthritis, Rheumatoid/pathology , Cartilage, Articular/pathology , Case-Control Studies , Female , Hand Joints/diagnostic imaging , Hand Joints/pathology , Humans , Male , Metacarpophalangeal Joint/pathology , Middle Aged , Organ Size , Radiography , Reproducibility of Results , Ultrasonography
6.
Z Geburtshilfe Neonatol ; 216(1): 34-6, 2012 Feb.
Article in German | MEDLINE | ID: mdl-22331526

ABSTRACT

Sirenomelia is a rare, but complex and lethal malformation. It is caused by a primary defect of the caudal axial skeleton and damage to the primary streak, which appears due to a vascular steal phenomenon. Sirenomelia appears sporadic with an incidence of 1-64,000 births. A risk for sirenomelia can be also found in patients with poorly controlled diabetes mellitus and in monocygotic twins. Leading ultrasound findings are fusioned lower extremities, bilateral renal agenesis, single umbilical artery and a distinct oligohydramnios. 3D ultrasound and color Doppler sonography can additionally be used for diagnostic, as well as amnioninfusion. There are 3 forms of sirenomelia, depending on missing or presence of the feet it is distinguished as sympus apus, monopus or dipus. We are presenting a case of sirenomelia with sympus dipus, which was transferred for further diagnostic of severe oligohydramnios in 21 weeks of gestation by the gynecologist.


Subject(s)
Ectromelia/complications , Ectromelia/diagnostic imaging , Oligohydramnios/diagnostic imaging , Oligohydramnios/etiology , Pregnancy Trimester, Second , Abnormalities, Multiple/diagnostic imaging , Abnormalities, Multiple/pathology , Abortion, Eugenic , Adult , Ectromelia/pathology , Female , Humans , Infant, Newborn , Kidney/abnormalities , Kidney/diagnostic imaging , Kidney/pathology , Oligohydramnios/pathology , Pregnancy , Ultrasonography, Prenatal , Umbilical Arteries/abnormalities , Umbilical Arteries/diagnostic imaging
7.
Arthritis Rheum ; 64(5): 1323-8, 2012 May.
Article in English | MEDLINE | ID: mdl-22130974

ABSTRACT

OBJECTIVE: Anti-citrullinated protein antibodies (ACPAs) are highly specific for rheumatoid arthritis (RA) and are present years before the onset of symptoms. The avidity of autoantibodies can have a strong impact on their effector potency. This study was undertaken to analyze the avidity of ACPAs in serum samples obtained from ACPA-positive healthy individuals (predisease), patients with early disease, and patients with established RA as well as the avidity maturation over time in samples from healthy subjects who later developed RA. METHODS: We measured ACPA avidity in serum samples from ACPA-positive healthy individuals, symptomatic individuals, and patients with established RA in 5 collections from The Netherlands, Canada, and Austria. We determined the dynamics of avidity maturation of ACPAs from the predisease stage to established disease in 1 case from the native North American population and in 10 cases from a Dutch blood donor cohort. RESULTS: The overall ACPA response was characterized by low-avidity antibodies. Higher-avidity ACPAs were observed in symptomatic patients only, while low-avidity ACPAs were observed in both healthy subjects and patients. In longitudinal samples obtained from subjects prior to disease onset, ACPA avidity increased over time until disease onset. No further avidity maturation was observed after disease onset. CONCLUSION: Our findings indicate that avidity maturation of the ACPA response takes place prior to disease onset.


Subject(s)
Antibody Affinity/immunology , Arthritis, Rheumatoid/immunology , Autoantibodies/immunology , Immunization, Secondary , Peptides, Cyclic/immunology , Longitudinal Studies , Time Factors
8.
Ophthalmologe ; 102(10): 981-6, 2005 Oct.
Article in German | MEDLINE | ID: mdl-15812644

ABSTRACT

BACKGROUND: ABO blood group antigens are only expressed by the epithelial cells of normal human corneas. Since AB0 blood group antigens are also known to be expressed on stromal and endothelial cells of inflamed corneas, this study aimed to investigate the extend of ABO blood group antigen expression in corneal allograft failures. MATERIAL AND METHODS: Twenty-two failed corneal allografts of 22 patients were examined. In 12 cases the patients had clinically proven corneal allograft rejection. In 10 cases there was no evident history of allograft rejection and the diagnosis graft failure due to chronic endothelial cell loss was made. Immunohistochemical staining of paraffin embedded sections was performed with monoclonal mouse antibodies to human blood group antigen A or B using the streptavidin-biotin-peroxidase complex technique. RESULTS: Blood group antigens A or B were expressed by stromal keratocytes in 5 out of 12 and by endothelial cells in 7 out of 12 corneas with clinically proven immunologic graft rejection. Corneal transplants with chronic endothelial cell loss expressed blood group antigens A and/or B on the endothelial cells in three out of ten cases. CONCLUSION: The results of this study show that ABO blood group antigens can be up-regulated in cases of corneal allograft failure, especially in cases of immune mediated graft rejection. This phenomenon might play a role in corneal allograft rejection.


Subject(s)
ABO Blood-Group System , Corneal Transplantation , Graft Rejection/immunology , Adult , Aged , Aged, 80 and over , Cornea/cytology , Cornea/immunology , Corneal Transplantation/immunology , Female , Humans , Immunohistochemistry , Male , Middle Aged , Time Factors
10.
Urologe A ; 43(9): 1120-2, 2004 Sep.
Article in German | MEDLINE | ID: mdl-15235776

ABSTRACT

In this report we describe the case of a testicular schwannoma in a human. Histologically, the tumor presented as a plexiform schwannoma. This rare benign peripheral nerve sheath tumor is an uncommon nodular variant of schwannoma, which mimics plexiform neurofibroma by its multinodular growth.


Subject(s)
Neurilemmoma/pathology , Neurofibroma, Plexiform/pathology , Rare Diseases/pathology , Testicular Neoplasms/pathology , Diagnosis, Differential , Humans , Male , Middle Aged
11.
Pathologe ; 23(4): 260-83, 2002 Jul.
Article in German | MEDLINE | ID: mdl-12185780

ABSTRACT

New developments in neuro-oncology have prompted an update of the World Health Organization (WHO) classification of tumors of the nervous system. Major changes include the addition of new entities and the refinement of criteria for the diagnosis and grading of various neoplasms, in particular the meningiomas. As novel clinico-pathological entities, the chordoid glioma of the third ventricle, the atypical teratoid/rhabdoid tumor (AT/RT), the solitary fibrous tumor, and the perineurioma have been listed. The former lipomatous medulloblastoma of the cerebellum, previously incorporated in the family of embryonal tumors, is now classified as cerebellar liponeurocytoma. The term mixed pineocytoma/pineoblastoma has been replaced by pineal parenchymal tumor of intermediate differentiation. Furthermore, the large cell medulloblastoma and the tanycytic ependymoma were established as novel tumor variants. A separate chapter on the peripheral neuroblastic tumors has now been included in the classification. Substantial revisions were introduced in the meningioma chapter. For both atypical meningioma WHO grade II and anaplastic meningioma WHO grade III, histopathological criteria are now precisely defined. An important new addition to the WHO 2000 classification of nervous system tumors is the inclusion of molecular pathology findings. With this combination of pathology and genetics it has set the stage for a new format of the WHO tumor classification series.


Subject(s)
Nervous System Neoplasms/classification , Astrocytoma/pathology , Brain Neoplasms/pathology , Diagnosis, Differential , Humans , Meningioma/pathology , Nervous System Neoplasms/genetics , Nervous System Neoplasms/pathology , Peripheral Nervous System Neoplasms/pathology , World Health Organization
12.
J Pathol ; 194(2): 201-6, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11400149

ABSTRACT

Extracellular matrix-degrading enzymes are crucial for cancer metastases. One group of enzymes that has been increasingly implicated in the breakdown of the extracellular matrix, and hence the intravasation and dissemination of tumour cells, is the family of metalloproteinases. In the recent past, increasing efforts have led to the development of more or less specific matrix metalloproteinase (MMP) inhibitors. Data concerning the molecular nature and timing of the contribution of MMPs to tumour spread is of paramount importance in clarifying which MMP is an appropriate target for more selective MMP inhibition in future tumour therapy. This study immunohistochemically characterized the expression pattern of MMP-2, -3, and -9 in 26 uveal melanomas. Forty-six per cent of the uveal melanomas expressed MMP-2 and/or MMP-9. MMP-3 expression was seen in 17 out of 26 uveal melanomas. MMP-9, previously shown to play an important part in tumour dissemination, was predominantly present in epithelioid melanomas (71.4%) or the epithelioid portion of mixed cell uveal melanomas (67%), whereas only one out of ten spindle cell melanomas showed MMP-9 expression (10%). MMP-2 and MMP-9 expression was associated with a significantly higher incidence of metastatic disease. The survival rate of patients with MMP-2-positive melanomas was 31% vs. 85% for patients with MMP-2-negative (p<0.05); for MMP-9-positive uveal melanomas the survival rate was 27% vs. 85% with MMP-9-negative uveal melanomas (p<0.04). The fact that patients suffering from TIMP-1- as well as TIMP-2-positive uveal melanomas tended to show a better survival rate (72% vs. 45% for TIMP-1; 88% vs. 37% for TIMP-2) supports the view that proteolytic enzymes are of importance in tumour spread.


Subject(s)
Matrix Metalloproteinase 9/analysis , Melanoma/enzymology , Uveal Neoplasms/enzymology , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , Female , Follow-Up Studies , Humans , Immunohistochemistry , Male , Matrix Metalloproteinase 2/analysis , Matrix Metalloproteinase 3/analysis , Melanoma/mortality , Middle Aged , Statistics, Nonparametric , Survival Rate , Tissue Inhibitor of Metalloproteinase-1/analysis , Tissue Inhibitor of Metalloproteinase-2/analysis , Uveal Neoplasms/mortality
13.
Virchows Arch ; 438(4): 321-35, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11355165

ABSTRACT

As an anatomical interface between various tissues, the skull base harbors an exceptionally broad variety of neoplasms, some of which pose a major challenge for surgical pathology. The characterization of distinct immunohistochemical expression profiles and the identification of molecular genetic alterations associated with different tumor entities have significantly advanced this field. The new World Health Organization (WHO) classification of tumors of the nervous system lists 15 histopathological variants of meningioma. Of clinical importance are those entities that carry an increased risk of recurrence and a poor prognosis, i.e., the atypical meningioma (WHO grade II), clear-cell meningioma (WHO grade II), chordoid meningioma (WHO grade II), rhabdoid meningioma (WHO grade III), papillary meningioma (WHO grade III), and anaplastic meningioma (WHO grade III). Diagnostic criteria for atypical and anaplastic meningioma variants have now been stringently defined. The differential diagnosis of meningiomas includes hemangiopericytoma, hemangioblastoma, solitary fibrous tumor, sarcomas, and chordoid neoplasms. Recent data highlight the importance of distinguishing chordoma and chondrosarcoma of the skull base since chondrosarcomas show a significantly better clinical outcome. Among the less common, aggressive tumor entities in this anatomical region, infiltrating pituitary adenoma/pituitary carcinoma, superficial malignant gliomas, rhabdomyosarcoma, olfactory neuroblastoma, various sarcomas, and malignant lymphoma must be considered. Profiles of molecular genetic alterations have been established for several of these neoplasms and may facilitate the differential diagnosis. This review summarizes recent developments in the histopathological characterization, classification, and molecular pathology of neoplasms arising at the skull base.


Subject(s)
Skull Base Neoplasms/pathology , Biomarkers, Tumor/analysis , Chordoma/chemistry , Chordoma/classification , Chordoma/genetics , Chordoma/pathology , DNA, Neoplasm/analysis , Diagnosis, Differential , Meningeal Neoplasms/chemistry , Meningeal Neoplasms/classification , Meningeal Neoplasms/genetics , Meningeal Neoplasms/pathology , Meningioma/chemistry , Meningioma/classification , Meningioma/genetics , Meningioma/pathology , Neoplasm Staging , Neurilemmoma/chemistry , Neurilemmoma/classification , Neurilemmoma/genetics , Neurilemmoma/pathology , Skull Base Neoplasms/chemistry , Skull Base Neoplasms/classification , Skull Base Neoplasms/genetics
14.
J Clin Invest ; 107(9): 1183-92, 2001 May.
Article in English | MEDLINE | ID: mdl-11342582

ABSTRACT

Lipoprotein lipase (LpL) binding to heparan sulfate proteoglycans (HSPGs) is hypothesized to stabilize the enzyme, localize LpL in specific capillary beds, and route lipoprotein lipids to the underlying tissues. To test these hypotheses in vivo, we created mice expressing a human LpL minigene (hLpL(HBM)) carrying a mutated heparin-binding site. Three basic amino acids in the carboxyl terminal region of LpL were mutated, yielding an active enzyme with reduced heparin binding. Mice expressing hLpL(HBM) accumulated inactive human LpL (hLpL) protein in preheparin blood. hLpL(HBM) rapidly lost activity during a 37 degrees C incubation, confirming a requirement for heparin binding to stabilize LPL: Nevertheless, expression of hLpL(HBM) prevented the neonatal demise of LpL knockout mice. On the LpL-deficient background hLpL(HBM) expression led to defective targeting of lipids to tissues. Compared with mice expressing native hLpL in the muscle, hLpL(HBM) transgenic mice had increased postprandial FFAs, decreased lipid uptake in muscle tissue, and increased lipid uptake in kidneys. Thus, heparin association is required for LpL stability and normal physiologic functions. These experiments confirm in vivo that association with HSPGs can provide a means to maintain proteins in their stable conformations and to anchor them at sites where their activity is required.


Subject(s)
Heparan Sulfate Proteoglycans/metabolism , Heparin/metabolism , Lipoprotein Lipase/metabolism , Amino Acids, Diamino/genetics , Animals , Binding Sites/genetics , Blotting, Northern , Chromatography, Affinity , Chylomicrons/metabolism , Enzyme Stability , Fat Emulsions, Intravenous/metabolism , Female , Humans , Lipoprotein Lipase/blood , Lipoprotein Lipase/genetics , Mice , Mice, Transgenic , Muscles/metabolism , Muscles/pathology , Mutation , Palmitates/metabolism
16.
Neuroradiology ; 41(7): 504-7, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10450844

ABSTRACT

Metastasising chordomas are extremely rare and only four cases with drop metastases have been reported. We report a patient with an intracranial chondroid chordoma, typically involving the clivus, treated by repeated resection, percutaneous transluminal embolisation and radiosurgery. During follow-up with MRI asymptomatic intradural drop metastases were observed throughout the spine, with transgression of the intervertebral foramen, forming a "dumbbell".


Subject(s)
Chordoma/secondary , Meningeal Neoplasms/secondary , Skull Base Neoplasms/pathology , Adult , Chordoma/diagnosis , Chordoma/therapy , Cranial Fossa, Posterior , Dura Mater/pathology , Humans , Magnetic Resonance Imaging , Male , Skull Base Neoplasms/diagnosis , Skull Base Neoplasms/therapy
17.
J Neurol ; 246(7): 556-61, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10463356

ABSTRACT

Hereditary spastic paraplegia is a group of clinically and genetically heterogeneous disorders consisting of pure and complicated forms. A variant with the additional features of severe atrophy of the small hand muscles, dysarthria, mental retardation, and short stature has been termed Troyer syndrome (MIM#275900) after the name of Old Order Amish families suffering from these symptoms. We report here an Austrian family with two individuals who exhibit all the features of Troyer syndrome, and provide additional data on this disorder. Electrophysiological studies showed chronic denervation and reduced motor nerve conduction velocities but normal sensory potentials. Muscle biopsy revealed a neurogenic pattern while the sural nerve was normal on histological examination. Brain abnormalities on magnetic resonance imaging consisted of a thin corpus callosum with a poorly developed cingulate gyrus and mild periventricular signal hyperintensities. These findings characterize the Troyer syndrome as a disorder of the first and second motor neuron with additional damage in the brain. The morphological features observed in this family may contribute to the grouping and subsequent understanding of complicated forms of hereditary spastic paraplegia, together with similar observations in other, more recently reported families.


Subject(s)
Agenesis of Corpus Callosum , Motor Neuron Disease/genetics , Muscle, Skeletal/pathology , Spastic Paraplegia, Hereditary/genetics , Adult , Biopsy , Corpus Callosum/pathology , Female , Hand , Humans , Magnetic Resonance Imaging , Motor Neuron Disease/physiopathology , Neural Conduction , Pedigree , Spastic Paraplegia, Hereditary/physiopathology , Syndrome
18.
Clin Anat ; 12(4): 266-71, 1999.
Article in English | MEDLINE | ID: mdl-10398386

ABSTRACT

Myogelosis is a common diagnosis in the case of chronic pain conditions, especially in the region of the pectoral girdle musculature, the glutei muscles, and the erector spinae muscle. Although such indurative areas continue to be palpable even on the cadaver, few studies concerning the morphological substrate of these areas have been undertaken. Selected biopsies as well as larger tissue samples were taken from 11 corpses and prepared for histological study. Following staining, the frozen sections were examined morphometrically. A histologically constant, significant morphological alteration was found in the areas of concern. The spaces between the individual muscle fibers of healthy muscle tissue appear relatively wide, the endomysium of the myogelotic area are clearly narrowed. Split fibers, ragged red fibers, Type II fiber atrophy, and fibers with a moth-eaten appearance have been detected. The morphometry shows considerable increase in thickness of the affected muscle fibers, suggestive of a pathological, local hypertrophy. The changes described may well represent a fixed condition, so that it should not be surprising that myogelosis therapy is difficult and protracted.


Subject(s)
Muscle Hypertonia/pathology , Muscle, Skeletal/pathology , Aged , Aged, 80 and over , Biopsy, Needle , Cadaver , Culture Techniques , Female , Humans , Male , Middle Aged , Muscle, Skeletal/anatomy & histology , Reference Values
19.
Pacing Clin Electrophysiol ; 22(3): 531-3, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10192865

ABSTRACT

After twenty-five years of therapy with different unifocal pacemaking systems, an 84-year old male patient developed a nonseptic pacemaker decubitus. A rare incidental finding of invasive ductal carcinoma of the right mammary gland was surgically treated by a generous excision of the tumor and by consecutive modified radical mastectomy. According to published literature, the association of invasive ductal carcinoma arising from a pacemaker pocket decubitus and followed by curative treatment has not been previously reported. We do conclude that pacemaker generators in close relationship to the mammary gland should be considered with suspicion.


Subject(s)
Breast Neoplasms, Male/etiology , Carcinoma, Ductal, Breast/etiology , Pacemaker, Artificial/adverse effects , Ulcer/etiology , Aged , Aged, 80 and over , Breast Neoplasms, Male/pathology , Breast Neoplasms, Male/surgery , Carcinoma, Ductal, Breast/pathology , Carcinoma, Ductal, Breast/surgery , Humans , Male , Mastectomy, Radical
20.
Acta Ophthalmol Scand ; 77(1): 31-2, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10071144

ABSTRACT

PURPOSE: To investigate the possible role of UV-radiation in the development of conjunctival malignant melanoma. N-ras mutations are frequently found in cutaneous melanomas of sun-exposed body areas. UV-radiation is thought to induce mutations in the N-ras gene, that convert these genes into active oncogenes. The presence of N-ras mutations has been considered an indicator for UV-exposure in the development of melanomas on sun-exposed body sides. METHODS: We analyzed six paraffin-embedded conjunctival melanomas for mutations of the N-ras gene. Codons 12, 13 and 61 were amplified using polymerase chain reaction and sequenced. RESULTS: We could not detect point mutations of the N-ras gene in our samples. CONCLUSION: Since we could not find deviations from the wild type sequence in the N-ras gene, our study does not support UV-exposure as being causative in the development of conjunctival melanoma.


Subject(s)
Conjunctival Neoplasms/genetics , Genes, ras/genetics , Melanoma/genetics , Neoplasms, Radiation-Induced/genetics , Ultraviolet Rays/adverse effects , Codon , Conjunctival Neoplasms/etiology , DNA Primers/chemistry , DNA, Neoplasm/analysis , Genes, ras/radiation effects , Humans , Melanoma/etiology , Neoplasms, Radiation-Induced/etiology , Point Mutation , Polymerase Chain Reaction , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...